19 Amendments of Françoise GROSSETÊTE related to 2011/0402(CNS)
Amendment 178 #
Proposal for a decision
Recital 11 a (new)
Recital 11 a (new)
(11 a) International cooperation is essential to achieve the stated aims of all parts of the specific programme, and international cooperation projects targeted at countries or groups of countries on horizontal or priority issues should be implemented under each part.
Amendment 335 #
Proposal for a decision
Annex 1 – point 2 – paragraph 2 – introductory part
Annex 1 – point 2 – paragraph 2 – introductory part
The focus of international cooperation in Horizon 2020 will be on cooperation with three major country groupings: industrialised and emerging economies, enlargement and neighbourhood countries and developing countries.
Amendment 336 #
Proposal for a decision
Annex 1 – point 2 – paragraph 2 – point 1
Annex 1 – point 2 – paragraph 2 – point 1
Amendment 338 #
Proposal for a decision
Annex 1 – point 2 – paragraph 2 – point 2
Annex 1 – point 2 – paragraph 2 – point 2
Amendment 341 #
Proposal for a decision
Annex 1 – point 2 – paragraph 2 – point 3
Annex 1 – point 2 – paragraph 2 – point 3
Amendment 342 #
Proposal for a decision
Annex 1 – point 2 – paragraph 3
Annex 1 – point 2 – paragraph 3
Amendment 348 #
Proposal for a decision
Annex 1 – point 2 – paragraph 5
Annex 1 – point 2 – paragraph 5
Amendment 350 #
Proposal for a decision
Annex 1 – point 2 – paragraph 6 – point a
Annex 1 – point 2 – paragraph 6 – point a
(a) The continuation and strengthening of the European and Developing Countries Clinical Trials Partnership (EDCTP2) on clinical trials for medical interventions against HIV, malaria and tuberculosis;
Amendment 360 #
Proposal for a decision
Annex 1 – point 3 – paragraph 4
Annex 1 – point 3 – paragraph 4
Cross-cutting action will also be vital in stimulating the interactions between the societal challenges and the enabling and industrial technologies needed to generate major technological breakthroughs. Examples of where such interactions may be developed are: the domain of eHealth, smart grids, intelligent transport systems, mainstreaming of climate actions, nanomedicine, testing methods that are more predictive and more relevant to human beings, risk assessment, medical research, advanced materials for lightweight vehicles or the development of bio-based industrial processes and products. Strong synergies will therefore be fostered between the societal challenges and the development of generic enabling and industrial technologies. This will be explicitly taken into account in developing the multi-annual strategies and the priority setting for each of these specific objectives. It will require that stakeholders representing the different perspectives are fully involved in the implementation and in many cases, it will also require actions which bring together funding from the enabling and industrial technologies and the societal challenges concerned.
Amendment 424 #
Proposal for a decision
Annex 1 – section 1 – point 3 – point 3.3 – paragraph 2
Annex 1 – section 1 – point 3 – point 3.3 – paragraph 2
European funding will support short term exchanges of research and innovation staff within partnerships of universities, research institutions, businesses, SMEs and other socio-economic actors among Europe, as well as between Europe and third countries to reinforce international cooperation. Specific measures will be taken with a view to strengthening the research capacities of developing countries. It will be open to research and innovation staff at all career levels, from the most junior (post-graduate) to the most senior (management), including also administrative and technical staff.
Amendment 469 #
Proposal for a decision
Annex 1 – section 2 – point 1 – paragraph 12 – indent 3 a (new)
Annex 1 – section 2 – point 1 – paragraph 12 – indent 3 a (new)
- the development and use of testing methods which are more predictive and relevant to the realities of human life, risk assessment and medical research
Amendment 604 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.1 – paragraph 2
Annex 1 – section 3 – point 1 – point 1.1 – paragraph 2
In particular, a better understanding of the environment as a determinant of health will require human-centred integrated molecular biological, epidemiological and toxicological approaches to investigate health- environment relationships and to elucidate the underlying mechanisms of illnesses and human toxicity, including studies of modes of action of chemicals, combined exposures to pollution and other environmental and climate related stressors, integrated toxicological testing as well as alternatives to animal testing. Innovative approaches to exposure assessment are needed using new- generation human-centred biomarkers based on 'omics' and epigenetics, human biomonitoring, personal exposure assessments and modelling to understand combined, cumulative and emerging exposures, integrating socio-economic and behavioural factors. Improved links with environmental data using advanced information systems will be supported.
Amendment 610 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.3 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.3 – paragraph 1
Human populations are under threat from new and emerging infections (including those resulting from climate change), from drug resistance to existing pathogens and from other direct and indirect consequences of climate change. Improved methods for surveillance, early warning networks, health service organisation and preparedness campaigns are needed for the modelling of epidemics, for effective pandemic response, for responses to non infectious disease consequences of climate change, as are efforts to maintain and enhance capabilities to combat drug resistant infectious disease. In order to face up to these global challenges, the EU will, in partnership with the countries concerned, implement measures aimed at achieving concrete results in health policy, improving health care services and supporting their own research capacity.
Amendment 616 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.5 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.5 – paragraph 1
There is a need for more effective preventive vaccines (or alternative preventive interventions) and evidence- based vaccination schemes for an expanded range of diseases. This relies on a better understanding of disease and disease processes and their consequent epidemics, more predictive, effective pre-clinical safety assessments (such as coherent approaches combined with other, non- animal or reductive approaches), and that clinical trials and associated studies are undertaken.
Amendment 620 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.6 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.6 – paragraph 1
An improved understanding of health, disease and disease processes at all ages is needed to develop new and more effective diagnostics. Innovative and existing technologies will be developed with the goal of significantly improving disease outcomes throughso that they can be adapted to different environmental and socio-economic conditions, with the goal of ensuring earlier, more accurate diagnosis and by allowing for more patient- adapted treatment.
Amendment 622 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.6 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.6 – paragraph 1
An improved understanding of health, disease and disease processes at all ages is needed to develop new and more effective diagnostics. Innovative and existing technologies will be developed with the goal of significantly improving disease outcomes through earlier, more accurate diagnosis and by allowing for more patient-adapted treatment. Mutations causing genetic diseases will be identified and the availability of diagnostic tests will be significantly increased.
Amendment 628 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.8 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.8 – paragraph 1
There is a need to support the improvement of cross-cutting support technologies for drugs, biotherapy, vaccines and other therapeutic approaches, including transplantation, gene and cell therapy, including inter-disciplinary approaches (e.g. biomathematics, bioinformatics and nuclear medicine); to increase success in the drug and vaccine development process (including alternative methods to replace classical safety and effectiveness testing e.g. the development of new methods); to develop regenerative medicine approaches, including approaches based on stem cells; to develop improved medical and assistive devices and systems; to maintain and enhance our ability to combat communicable, rare, major and chronic diseases and undertake medical interventions that depend on the availability of effective antimicrobial drugs; and to develop comprehensive approaches to treat co-morbidities at all ages and avoid poly-pharmacy. These improvements will facilitate the development of new, more efficient, effective and sustainable treatments for disease and for the management of disability.
Amendment 636 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.9 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.9 – paragraph 1
Clinical trials are the means to transfer biomedical knowledge to application in patients and support for these will be provided, as well as for the improvement of their practice. Examples include the development of better methodologies to allow trials to focus on relevant population groups, including those suffering from rare diseases, other concomitant diseases and/or already undergoing treatment, the determination of comparative effectiveness of interventions and solutions, as well as enhancing the use of databases and electronic health records as data sources for trials and knowledge transfer. Specific support should be ensured for the preclinical and/or clinical development of substances with a clear potential to address largely unmet medical needs, such as designated orphan drugs. Similarly, support for the transfer of other types of interventions such as those related to independent living into real world environments will be provided.
Amendment 659 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.16 – paragraph 1
Annex 1 – section 3 – point 1 – point 1.16 – paragraph 1
Support provided will cover the full spectrum of activities from capacity- building, knowledge and technology transfer to large (including health policy), implementation, monitoring and assessment of large-scale demonstration actions, leading to scalable solutions for European and beyond.